Skip to main content
. 2014 Jan 9;3(1):1–24. doi: 10.3390/jcm3010001

Figure 3.

Figure 3

Forest plot of comparison: Overall risk of SREs in breast cancer bone metastases: denosumab versus bisphosphonate. Reproduced with permission from ©Cochrane Collaboration [25].